Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?
Gampenrieder SP, Rinnerthaler G, Greil R. Gampenrieder SP, et al. Breast Care (Basel). 2014 Oct;9(5):323-30. doi: 10.1159/000368710. Breast Care (Basel). 2014. PMID: 25759612 Free PMC article. Review.
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S, Hauser-Kronberger C, Ulmer H, Greil R. Hohla F, et al. Int J Oncol. 2014 Jan;44(1):319-26. doi: 10.3892/ijo.2013.2176. Epub 2013 Nov 15. Int J Oncol. 2014. PMID: 24247204
Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Gampenrieder SP, Romeder F, Muß C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R. Gampenrieder SP, et al. Anticancer Res. 2014 Jan;34(1):227-33. Anticancer Res. 2014. PMID: 24403467 Clinical Trial.
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, Weltermann A, Thaler J, Hufnagl C, Gampenrieder SP, Rinnerthaler G, Ressler S, Ulmer H, Greil R. Pircher M, et al. Anticancer Res. 2015 Jan;35(1):517-21. Anticancer Res. 2015. PMID: 25550597 Clinical Trial.
miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites.
Rinnerthaler G, Hackl H, Gampenrieder SP, Hamacher F, Hufnagl C, Hauser-Kronberger C, Zehentmayr F, Fastner G, Sedlmayer F, Mlineritsch B, Greil R. Rinnerthaler G, et al. Int J Mol Sci. 2016 Jan 26;17(2):156. doi: 10.3390/ijms17020156. Int J Mol Sci. 2016. PMID: 26821018 Free PMC article.
Adjuvant medical treatment for breast cancer in elderly and old women.
Westphal T, Rinnerthaler G, Mlineritsch B. Westphal T, et al. Memo. 2016;9:17-19. doi: 10.1007/s12254-016-0258-4. Epub 2016 Mar 8. Memo. 2016. PMID: 27069512 Free PMC article. Review.
Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP, Hufnagl C, Brechelmacher S, Huemer F, Hackl H, Rinnerthaler G, Romeder F, Monzo Fuentes C, Morre P, Hauser-Kronberger C, Mlineritsch B, Greil R. Gampenrieder SP, et al. Pharmacogenomics J. 2017 Jul;17(4):344-350. doi: 10.1038/tpj.2016.25. Epub 2016 May 3. Pharmacogenomics J. 2017. PMID: 27139155
CDK4/6 inhibition in luminal breast cancer.
Gampenrieder SP, Rinnerthaler G, Greil R. Gampenrieder SP, et al. Memo. 2016;9:76-81. doi: 10.1007/s12254-016-0268-2. Epub 2016 Jun 20. Memo. 2016. PMID: 27429659 Free PMC article. Review.
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggl A, Greil R, Egle A. Magnes T, et al. Pharmacogenomics J. 2018 May 22;18(3):474-479. doi: 10.1038/tpj.2017.37. Epub 2017 Jul 18. Pharmacogenomics J. 2018. PMID: 28719596
40 results
Jump to page